Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021469 | 0.81 | PKM (0.41) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3196805 | 0.81 | CA2 (0.32) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5884292 | 0.81 | SLC6A3 (0.35) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31282934 | 0.79 | ALDH1A1 (0.32) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3600443 | 0.79 | SMN1; SMN2 (0.50) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20681165 | 0.77 | HRH1 (0.30) | — | |
| SCHEMBL21963140 | 0.77 | SLC6A3 (0.40) | NPC1 | |
| SCHEMBL15349355 | 0.77 | — | — | |
| SCHEMBL21963406 | 0.76 | NPC1 (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15349359 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | NPC1 8/4885RAB9A 4272/4885SMN1; SMN2 4859/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | NPC1 8/4885RAB9A 4272/4885SMN1; SMN2 4859/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | NPC1 8/4885RAB9A 4272/4885SMN1; SMN2 4859/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | NPC1 8/4885RAB9A 4272/4885SMN1; SMN2 4859/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | NPC1 8/4885RAB9A 4272/4885SMN1; SMN2 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.